This month’s roundup covers hip fracture risk, improvements in diabetes-associated risk assessment, and a model to calculate gestational diabetes risk.
New studies on diabetes show current use of glucose-lowering drugs is associated with hip fracture in patients with type 2 mellitus (T2DM); standard methods of assessing bone health may underestimate the amount of risk fracture in diabetes patients; and a new tool can identify obese women who are at high risk of developing gestational DM early in pregnancy.
Endocrinology News Roundup: Fracture, Gestational Diabetes Risks. January 2017
Glucose-Lowering Drugs Increase Risk of Hip Fracture Abstract link.
Patients with T2DM have an increased risk of hip fracture, which increases if they currently use glucose-lowering drugs.
Clinicians should be cautious when prescribing certain glucose-lowering drugs to T2DM patients with other risk factors for fracture, including older age and previous major fractures.
The increased fracture risk associated with T2DM is not fully captured by bone mineral density (BMD) testing, leading to an increase in fracture risk above that predicted from BMD alone, according to a new review.
Adjustments can improve fracture risk prediction and help avoid systematically underestimating the risk of osteoporosis-related fractures in DM patients.
Identifying Women at Risk for Gestational Diabetes Abstract link.
Tools for early pregnancy identification of obese women at risk of gestational DM might enable targeted interventions in women who will benefit the most.
Earlier identification and intervention of high-risk obese women may help reduce the prevalence of gestational diabetes or complications associated with it.
